Últimas noticias sobre GD Culture Group (NASDAQ:GDC) Bolsa

GD Culture Group

GD Culture Group Ltd focuses its business on two segments mainly through the Company and two subsidiaries. 1) AI-driven digital human creation and customization; 2) Live streaming and e-commerce. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.

GD Culture Group Ltd

Macro Economic Events

News

Politics

Global

Economics

General

NVDA

Watching Nvidia; Reuters Report A Senior Congressional Staff Member Reportedly Said Nvidia Discussed Concerns About Hauwei's Growing AI Capabilities With U.S. Lawmakers

Morgan Stanley analyst Erik Woodring maintains Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) with a Underweight and raises the price target from $159 to $172.

Price Target

Analyst Ratings

GRMN

Morgan Stanley Maintains Underweight on Garmin, Raises Price Target to $172

RBC Capital analyst Walter Spracklin maintains Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) with a Outperform and lowers the price target from $122 to $121.

RBC Capital Maintains Outperform on Canadian Pacific Kansas, Lowers Price Target to $121

Morgan Stanley analyst Elizabeth Porter maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Equal-Weight and raises the price target from $14 to $18.

FRSH

Morgan Stanley Maintains Equal-Weight on Freshworks, Raises Price Target to $18

Morgan Stanley analyst Ryan Kenny maintains Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) with a Equal-Weight and raises the price target from $173 to $175.

Morgan Stanley Maintains Equal-Weight on Evercore, Raises Price Target to $175

RBC Capital analyst Ashish Sabadra reiterates Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) with a Sector Perform and maintains $315 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Automatic Data Processing, Maintains $315 Price Target

Morgan Stanley analyst Lauren Schenk maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Underweight and lowers the price target from $40 to $38.

ETSY

Morgan Stanley Maintains Underweight on Etsy, Lowers Price Target to $38

RBC Capital analyst Jonathan Atkin maintains American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) with a Outperform and raises the price target from $240 to $250.

RBC Capital Maintains Outperform on American Tower, Raises Price Target to $250

Morgan Stanley analyst Nathan Feather maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a Overweight and raises the price target from $70 to $74.

EBAY

Morgan Stanley Maintains Overweight on eBay, Raises Price Target to $74

WIIM

PTC shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 300 points on Thursday.
The Dow traded up 0.84% to 41,009.52 while the NASDAQ climbed 2.31% to 17,849.38. The S&amp;P 500 also rose, gaining, 1.30% to 5,641.55.
Check This Out: <a href="https://www.benzinga.com/25/05/45134238/top-2-real-estate-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Real Estate Stocks That May Keep You Up At Night In May</a>
Leading and Lagging Sectors Information technology shares rose by 3.3% on Thursday.
In trading on Thursday, health care stocks dipped by 2%.
Top Headline
McDonald&#8217;s Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) posted weaker-than-expected revenue for its first quarter.
The company reported first-quarter revenue decline of 3.4% year-on-year to $5.96 billion, missing the analyst consensus estimate of $6.09 billion. Adjusted EPS of $2.67 beat the consensus estimate of $2.66.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) shares shot up 22% to $4.5650 following better-than-expected quarterly earnings.</li>
<li>Shares of Classover Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>)got a boost, surging 239% to $3.87 after the company announced it entered into an equity purchase facility agreement with Solana Strategies Holdings.</li>
<li>MediaAlpha, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) shares were also up, gaining 20% to $10.09 following strong quarterly sales.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Organon &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) shares dropped 23% to $9.99 after the company reported first-quarter financial results and cut its quarterly dividend.</li>
<li>Shares of Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) were down 28% to $6.92 after the company posted first-quarter results.</li>
<li>Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) was down, falling 16% to $20.01 following first-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $58.61 while gold traded down 2.9% at $3,224.10.
Silver traded down 0.6% to $32.640 on Thursday, while copper rose 0.9% to $4.6480.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.03%, while London's FTSE 100 rose 0.06%.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei gaining 1.13%.
Economics
<ul>
<li>U.S. construction spending fell by 0.5% month-over-month to an annual rate of $2,196.1 billion in March.</li>
<li>The ISM manufacturing PMI declined to 48.7 in April compared to 49.0 in March, above market estimates of 48.</li>
<li>U.S. initial jobless claims increased by 18,000 to 241,000 in the week ending April 26, compared to market estimates of 224,000.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45135511/how-to-earn-500-a-month-from-apple-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Apple Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Markets

Trading Ideas

ARVN

CFLT

COMM

KIDZ

Dow Surges Over 300 Points; McDonald's Posts Weak Revenue

Morgan Stanley analyst Benjamin Swinburne maintains Clear Channel Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) with a Equal-Weight and lowers the price target from $2 to $1.5.

Morgan Stanley Maintains Equal-Weight on Clear Channel Outdoor, Lowers Price Target to $1.5

Morgan Stanley analyst Stephen Byrd maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Overweight and lowers the price target from $35 to $30.

Morgan Stanley Maintains Overweight on Bloom Energy, Lowers Price Target to $30

Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) reported on Thursday a first-quarter EPS loss of $(2.52), missing <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus of $(3.12)</a>, down from an EPS loss of $(3.07) a year ago.
The COVID-19 vaccine maker reported quarterly sales of $108 million, down from $167 billion a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/ac45128954/moderna-reports-first-quarter-2025-financial-results-and-provides-business-updates" rel="noreferrer noopener">consensus of $106.20 million</a>.
The decline was primarily driven by lower net product sales, which totaled $86 million in the quarter.
The reduction in product sales reflects lower vaccination rates compared to the same period last year and the continued normalization of COVID-19 into a seasonal commercial market, with demand expected to be concentrated in the second half of the year.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/45059756/trump-era-fda-appointees-request-new-trials-for-novavax-covid-vaccine-reportedly-delaying-approval-timeline" rel="noreferrer noopener">Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline</a>
The company reported $84 million in Spikevax sales in the first quarter of 2025, including $29 million in the U.S. and $55 million in international sales.
The company reported $2 million in mRESVIA sales in the first quarter of 2025. Moderna&#8217;s RSV vaccine for adults 60 and older was recently approved in Australia, <a href="https://www.benzinga.com/general/biotech/25/04/44876132/us-advisory-panel-votes-to-expand-recommendation-for-pfizer-gsks-rsv-vaccines-for-older-adults-below-60-years" target="_blank" rel="noreferrer noopener">Switzerland, Taiwan and the U.K</a>.
The cost of sales for the fourth quarter of 2024 was $739 million, which included third-party royalties of $45 million, inventory write-downs of $193 million, and wind-down costs of $259 million, including a non-cash charge of $238 million related to the termination of a contract manufacturing agreement.
Guidance:&nbsp;Moderna has reiterated its <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43727537/moderna-struggles-with-declining-q4-covid-vaccine-sales-stock-slides" rel="noreferrer noopener">2025 revenue outlook</a> of $1.5 billion to $2.5 billion, compared to a consensus of $2.14 billion. Moderna expects revenue of approximately $0.2 billion in the first half of the year, reflecting the seasonality of its respiratory business.
Moderna expanded its cost efficiency and prioritization programs and expects estimated GAAP operating costs of $5.4 to $5.7 billion in 2026, a reduction from the company&#8217;s previous estimate of $5.9 billion.
The company is announcing a new 2027 GAAP operating cost estimate of $4.7 to $5 billion, reducing estimated operating costs by $1.4 to $1.7 billion by 2027 compared to its 2025 estimate.
Moderna shared Phase 3 immunogenicity data for its flu/COVID combination vaccine (mRNA-1083) for adults aged 50 and older at its 2024 R&amp;D Day event.&nbsp;
The company submitted mRNA-1083 for regulatory approval in older adults in 2024. Based on FDA feedback confirming the need for Phase 3 flu efficacy data, Moderna expects an extended review timeline and is now targeting approval in 2026.
Moderna has deprioritized its flu/COVID combination vaccine (mRNA-1083) for adults aged 18-49.
MRNA Price Action: Moderna stock was down 4.52% at $27.25 at publication on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45141818/hf-sinclair-overcomes-tariff-headwinds-sees-q1-strength-in-midstream-and-lubricants" target="_blank" rel="noreferrer noopener">HF Sinclair Overcomes Tariff Headwinds, Sees Q1 Strength In Midstream And Lubricants</a></li>
</ul>
Photo: Shutterstock

Biotech

Government

Large Cap

Guidance

Health Care

Movers

MRNA

Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026

JMP Securities analyst Greg Miller maintains The Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) with a Market Outperform and raises the price target from $175 to $185.

JMP Securities Maintains Market Outperform on The Hanover Insurance Gr, Raises Price Target to $185

Everest Group shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, Evercore ISI Group maintained an In-Line rating on the stock and lowered its price target from $400 to $396.

Morgan Stanley analyst Meta Marshall maintains Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Overweight and raises the price target from $73 to $100.

ANET

Morgan Stanley Maintains Overweight on Arista Networks, Raises Price Target to $100

JMP Securities analyst Greg Miller reiterates Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Market Outperform and maintains $750 price target.

JMP Securities Reiterates Market Outperform on Meta Platforms, Maintains $750 Price Target

Morgan Stanley analyst Kristine Liwag maintains AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) with a Equal-Weight and raises the price target from $101 to $111.

Morgan Stanley Maintains Equal-Weight on AerCap Holdings, Raises Price Target to $111

JMP Securities analyst Greg Miller reiterates Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Market Outperform and maintains $70 price target.

HOOD

JMP Securities Reiterates Market Outperform on Robinhood Markets, Maintains $70 Price Target

Press Releases

Peraso Inc. (NASDAQ: PRSO) Rockets Forward: Ladenburg Thalmann Issues Report Amid Explosive Q2 Growth, mmWave Surge FFIE, GDC, INBS, KAVL

GDC Announces SyncWaveX: Redefining Video Production with Direct Audio-to-Video AI Technology

"Must-Watch Stocks: News, Surging Trends in Tech, Biomed, Healthcare, Metals & Energy GDC, INBS, FFIE, PRSO, RJDG"

A New Standard in Drug Testing: Intelligent Bio (NASDAQ: INBS) Delivering Cost-Efficiency, Rapid Results, and Employee Dignity more stocks inside…

GDC Announces Strategic Partnership to Expand AI Creator Community

GDC Discontinues Livestreaming Gaming Business

GD Culture Group Limited Announces At-The-Market Equity Offering Program

GD Culture Group Limited Announces Pricing of Private Placement

GD Culture Group Limited Announces Closing of Private Placement

GD Culture Group Limited Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

AGRI

FFIE

FZRO

INBS

KAVL

PRSO

RJDG

SIGL

Able View Global Inc. - Class B Ordinary Shares

Able View Global

Advantage Solutions Inc. - Class A Common Stock

Advantage Solutions

AirNet Technology Inc. - American Depositary Shares, each representing one ordinary shares

Comments

GD Culture Group

Noticias

Últimas noticias sobre GD Culture Group (NASDAQ:GDC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL